An educational webinar focusing on the unmet needs in neurologic oncology, specifically glioma and glioblastoma, will be hosted by Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) from Melbourne, Australia and Indianapolis. The webinar aims to discuss how theranostics could potentially address these needs. The event is scheduled for June 23, 2026. Telix is a pharmaceutical company listed on the Australian Securities Exchange (ASX) and the NASDAQ with a primary focus on oncology therapeutics.